Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00475969 · ClinicalTrials.gov registry record · Phase 3
Duloxetine vs Placebo in the Treatment of General Anxiety
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 327
- Enrollment target
NCT00475969: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT00475969 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 327 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00475969, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 327 participants
- Enrollment target
Study Summary
To see if duloxetine 60 to 120 mg once daily (QD) is better than placebo in the treatment of generalized anxiety disorder (GAD).
Interventions
- DRUG placebo
- DRUG duloxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 327 participants |
| Start Date | 2004-08 |
| Est. Completion | 2005-06 |
| Phase | Phase 3 |
What the finished NCT00475969 record still lists
NCT00475969 is an interventional study that assigns participants to a tested intervention. The registered 327 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00475969 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00475969 about?
NCT00475969 is a clinical study titled "Duloxetine vs Placebo in the Treatment of General Anxiety". To see if duloxetine 60 to 120 mg once daily (QD) is better than placebo in the treatment of generalized anxiety disorder (GAD).
What is the current status of trial NCT00475969?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 327 participants. The study started on 2004-08. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00475969?
The interventions under investigation include: placebo (DRUG), duloxetine (DRUG).
Who is sponsoring clinical trial NCT00475969?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00475969's enrollment target sits among peer trials
327 1075th of 2000 higher than 926 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04486378 · 327 participants · Phase 2
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
- NCT06370182 · 327 participants · NA
Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA Funnel Catheter
- NCT05156983 · 328 participants · Phase 3
A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery
- NCT05380401 · 328 participants · NA
Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia